Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Use of first-generation ARBs

SF Shingo Fukuma
TI Tatsuyoshi Ikenoue
YY Yukari Yamada
YS Yoshiyuki Saito
JG Joseph Green
TN Takeo Nakayama
SF Shunichi Fukuhara
request Request a Protocol
ask Ask a question
Favorite

The main outcome was the use of first-generation ARBs (valsartan, candesartan, and losartan). Specifically, we began with the defined daily dose [DDD] per 1,000 persons. Then, for each month from April 2005 to March 2017, we computed the number of patients who received the drugs, that is, the country-level aggregated drug dose divided by the DDD (eTable 1).29 The DDD is “the average maintenance dose of the drug” and is approved by the World Health Organization (WHO). To calculate the numbers of patients receiving the drugs per 1,000 persons, we used the total number of residents of Japan from census data.27 Patients receiving angiotensin-converting-enzyme (ACE) inhibitors comprised the control group.

Copyright and License information:  ©2020 Shingo Fukuma et al.
This is an open access article distributed under the terms of Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

0/150

tip Tips for asking effective questions

+ Description

Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.

post Post a Question
0 Q&A